We Offer Worldwide Shipping
Login Wishlist

Vincristine Sulfate

$178

  • Brand : BIOFRON

  • Catalogue Number : BF-V3001

  • Specification : 98%

  • CAS number : 2068-78-2

  • Formula : C46H56N4O10.H2SO4

  • Molecular Weight : 923.04

  • PUBCHEM ID : 249332

  • Volume : 25mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-V3001

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

-20℃

Molecular Weight

923.04

Appearance

White needle crystal

Botanical Source

herbs of Hedera nepalensis K. Koch var. sinensis (Tobl.) Rehd.

Structure Type

Alkaloids

Category

Standards;Natural Pytochemical;API

SMILES

CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O

Synonyms

(3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0.0]nonadeca-4(12),5,7,9-tetraen-13-yl]-6-formyl-5-hydroxy-8-methoxy-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate de methyle sulfate (salt)/oncovin/VCR/Methyl-(3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0.0]nonadeca-4(12),5,7,9-tetraen-13-yl]-6-form/Vincrisul/(2'b)-22-oxovincaleukoblastine sulfate (1:1)/NovopharM/V5 PEPTIDE/kyocristine/(2'β)-22-Oxovincaleukoblastine sulfate (1:1)/22-Oxovincaleukoblastine Sulfate (1:1) (salt)/22-oxovincaleukoblastine sulfate/Vincristine sulfate salt/onkovin/methyl (3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0.0]nonadeca-4(12),5,7,9-tetraen-13-yl]-6-formyl-5-hydroxy-8-methoxy-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate sulfate (salt)/vincaleukoblastine, 22-oxo-, (2'b)-, sulfate (1:1)/yl-5-hydroxy-8-methoxy-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate sulfate (salt)/vincristin/methyl (3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0.0]nonadeca-4(12),5,7,9-tetraen-13-yl]-6-form/Vincristine sulfate/yl-5-hydroxy-8-methoxy-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazol-5-carboxylatsulfat(salt)/Vincaleukoblastine, 22-oxo-, (2'β)-, sulfate (1:1)/Methyl-(3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0.0]nonadeca-4(12),5,7,9-tetraen-13-yl]-6-formyl-5-hydroxy-8-methoxy-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazol-5-carboxylatsulfat(salt)/(3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0.0]nonadeca-4(12),5,7,9-tetraen-13-yl]-6-formyl-5-hy/Vincristine (sulfate)/Vincristine/vincaleukoblastine, 22-oxo-, (3β,4'β)-, sulfate (1:1)/22-Oxovincaleukoblastine sulfate salt,Leurocristine sulfate salt,VCR/droxy-8-methoxy-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate de methyle sulfate (salt)

IUPAC Name

methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate;sulfuric acid

Density

Solubility

Methanol

Flash Point

Boiling Point

273-281 °C

Melting Point

300 °C

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2915900000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:2068-78-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

27328933

Abstract

: Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs. The vinca alkaloid vincristine is a standard component of chemotherapy regimens used to treat ALL, because of its well-defined mechanism of action, demonstrated anticancer activity, and ability to be combined with other agents. However, the dosage of vincristine is frequently capped because of neurotoxicity concerns, and patients with large body surface areas are, therefore, almost always underdosed. Liposomal formulations have the ability to “passively” accumulate at sites of increased vasculature permeability and reduce the adverse effects of encapsulated relative to free drug. Vincristine sulfate liposome injection (VSLI) is a sphingomyelin/cholesterol-based liposome-encapsulated formulation that is delivered weekly in a 1-hour infusion. Based on the pharmacokinetics of the liposomal delivery system, vincristine is slowly released from the liposome and delivered into the tissues more efficiently than with the standard preparation, allowing a higher dose. This increase in therapeutic index from reduced toxicity is a valuable difference between the two formulations. VSLI is indicated for the treatment of adults with second or greater relapse and clinically advanced Philadelphia chromosome-negative ALL. For the first time, studies will be able to exploit the delivery of higher and uncapped doses of vincristine in randomized studies comparing first-line chemotherapy with standard vincristine versus VSLI in both ALL and lymphoma to determine whether VSLI is superior to conventional vincristine.
Implications for practice: This review summarizes the development of vincristine sulfate liposome injection, a new formulation of vincristine. The pharmacokinetics of liposomal drug delivery are examined, the limitations and advantages of conventional and liposomal vincristine are compared, and the use of vincristine sulfate liposome injection in clinical trials and case studies is included. Clinicians will be informed of a new chemotherapy agent that is indicated for the treatment of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia, whose disease has relapsed two or more times or whose leukemia has progressed after two or more regimens of antileukemia therapy.

KEYWORDS

Liposome; Marqibo; Pharmacokinetics; Vincristine; Vincristine sulfate liposome injection.

Title

Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia

Author

Dan Douer 1

Publish date

2016 Jul

PMID

15378106

Abstract

Purpose/objectives: To review the clinical pharmacology of vincristine sulfate, describe three types of medication errors associated with its use, and suggest strategies for vincristine sulfate medication error prevention.
Data sources: Published books and journal articles, online newsletters and documents, pharmaceutical manufacturers package inserts, and personal experience.
Data synthesis: Medication errors involving vincristine sulfate include overdosage (wrong dose), name confusion (wrong drug), and incorrect administration (wrong route).
Conclusions: Vincristine medication errors are preventable errors that usually result in serious patient harm and often are lethal.
Implications for nursing: Nurses need to be aware of the types of medication errors that can occur with chemotherapy agents and be familiar with clinical signs and symptoms associated with these errors. Nurses also need to promote patient safety by implementing specific strategies to prevent vincristine medication errors.

KEYWORDS

Liposome; Marqibo; Pharmacokinetics; Vincristine; Vincristine sulfate liposome injection.

Title

Preventing Vincristine Sulfate Medication Errors

Author

Lisa Schulmeister 1

Publish date

2004 Sep 17

PMID

29540104

Abstract

Background: The EPOCH regimen, consisting of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate, is typically administered by continuous infusion over four days to oncology inpatients. If the EPOCH regimen was available to be administered through portable elastomeric pumps, chemotherapy could be transitioned to an outpatient setting, reducing inpatient bed days and overall healthcare costs. However, a lack of stability data for the admixtures in the elastomeric infusion devices currently prevents the transition of the regime to an outpatient setting. The purpose of this study is to determine the physical and chemical stability of the admixture in polyisoprene elastomeric pumps under different storage conditions to support the transition of the EPOCH regime to an outpatient setting.
Methods: The physico-chemical stability of three admixtures at a range of clinically relevant concentrations compounded in polyisoprene elastomeric infusors was determined when refrigerated at 2-6℃ over a 14-day period followed by 35℃ up to 7 days in the dark, and under standardized fluorescent light to simulate scenarios in clinical practice.
Results: All tested admixtures were compatible and the drugs were stable in the elastomeric infusors for up to 14 days when stored at 2-6℃ followed by 7 days at 35℃ in the dark, with nominal losses of <5%. The major degradant of etoposide phosphate was its active form etoposide. There was no degradation (<1% loss) found when the admixture was exposed to a standardized fluorescent light dose of 80 klux-h (25℃) for 10 h. The temperature and light conditions the infusors were exposed to during the stability study were more severe than the conditions determine during clinical administration.
Conclusion: The extended stability of the three infusional admixtures compounded in elastomeric infusion pumps demonstrated herein permits advance preparation and storage of these drugs, reducing pharmacy compounding resources. The demonstrated stability at 35℃ and under light exposure, conditions more severe than those experienced during clinical practice, support continuous infusions for up to seven days from the elastomeric infusors without a loss of potency. The proven stability of the EPOCH regimens in the tested elastomeric infusion device supports the transition of treatment to an outpatient setting which will reduce inpatient bed days and overall healthcare costs.

KEYWORDS

EPOCH; doxorubicin; elastomeric infusion pump; etoposide; stability; vincristine.

Title

Stability of Vincristine Sulfate, Doxorubicin Hydrochloride and Etoposide Phosphate Admixtures in Polyisoprene Elastomeric Pump Supporting Transition of the EPOCH Regimen to Outpatient Care

Author

Darren Svirskis 1 , Sairam Behera 1 , Neera Naidoo 1 , Joanne Beachman 2 , Tarsha Raina 2 , Yongzhi Zhou 1 , Leanne Berkahn 2 , Ian Costello 2 , Yongchuan Gu 1 3

Publish date

2019 Jun


Description :

Vincristine sulfate is an antitumor vinca alkaloid which inhibits microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. It binds to microtubule with a Ki of 85 nM.